Research Site

Sendai, Miyagi 989-3122

1 studies enrolling now · 10 studies all time

What they study most

Breast Cancer, Dyslipidemia, Heart Failure, Hepatobiliary Cancers, Hyperlipidemia and Mixed Dyslipidemia, Multiple Myeloma, Postmenopausal Osteoporosis, Prostate Cancer, Stable Coronary Artery Disease (CAD), Myocardial Infarction

Studies at this site

• Observational Study Protocol: LIVER-R — Recruiting now
• Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis — Completed
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study — Completed
• Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia — Completed
• Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients — Stopped early
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases — Completed
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer — Stopped early